Ovation’s Panhematin Brochure, Monograph Draw FDA Warning Letter
This article was originally published in The Pink Sheet Daily
Executive Summary
Promotional materials for the porphyria therapy failed to include necessary risk information, including language from a “black box” warning in labeling, the agency says. Ovation says it has submitted a proposed remedial action plan to FDA.